FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912071335> ?p ?o ?g. }

• W2912071335 endingPage "35" @default.
• W2912071335 startingPage "35" @default.
• W2912071335 abstract "Abstract Background: With current multi-agent chemotherapy, 88-90% of children diagnosed with High Risk B-Acute Lymphoblastic Leukemia (HR B-ALL) will be cured. However, for those patients who relapse, ~ 1/3 will have central nervous system (CNS) involvement. Thus, adequate CNS disease control for children with HR B-ALL remains a challenge. AALL1131 was designed to determine if the administration of post-Induction age-adjusted triple intrathecal therapy (ITT) with methotrexate, hydrocortisone, and cytarabine, on a modified augmented Berlin-Frankfurt-Münster (MBFM) backbone, would improve 5-year disease free survival (DFS) of children with HR B-ALL compared to age-adjusted intrathecal methotrexate (IT MTX) alone. Methods: Patients with HR B-ALL included: National Cancer Institute (NCI) HR patients <13 years of age at diagnosis without adverse prognostic features [CNS leukemia at diagnosis (≥ 5 white blood cells in the cerebral spinal fluid with blasts on cytospin and/or clinical signs of CNS leukemia), iAMP21, KMT2A (MLL) rearrangement, or hypodiploidy (<44 chromosomes and/or DNA index <0.81)] who had bone marrow minimal residual disease (BM MRD) <0.01% on Induction day 29; and NCI standard risk (SR) patients lacking favorable cytogenetics (ETV6-RUNX1 fusion or trisomy of chromosomes 4 and 10) who had peripheral blood MRD ≥1% on day 8 and BM MRD <0.01% on Induction day 29, and NCI SR B-ALL patients with favorable cytogenetics who had BM MRD ≥0.01% on Induction day 29. Newly diagnosed children with HR B-ALL were randomized post-Induction in a 1:1 fashion to receive ITT versus IT MTX. A total of 21-26 doses of post-Induction intrathecal therapy was administered during Consolidation (n=4), Interim Maintenance (n=2), Delayed Intensification (n=3), and Maintenance (n=12 for girls, n=16 for boys). Results: The post-Induction HR B-ALL randomization was closed to accrual on March 19, 2018 following planned interim monitoring that revealed a futility boundary was crossed, concluding the inability to show the superiority of ITT compared to IT MTX. Five-year DFS rates for IT MTX versus ITT were 93±3.8% and 90±4.3%, p value=0.86. The corresponding estimated hazard ratio (HR) of IT MTX vs ITT is 1.285; 95% CI of (0.822, 2.01). There were no differences in toxicities observed in patients receiving ITT compared to IT MTX. As such, the study was amended to prescribe IT MTX to all patients. Conclusion: The administration of post-induction age adjusted ITT did not improve 5-year DFS of children with HR B-ALL without CNS leukemia. IT MTX remains the standard of care for CNS prophylaxis. Disclosures Burke: Shire: Speakers Bureau; JAZZ: Speakers Bureau; AMGEN: Speakers Bureau." @default.
• W2912071335 created "2019-02-21" @default.
• W2912071335 creator A5001477884 @default.
• W2912071335 creator A5006250220 @default.
• W2912071335 creator A5010578315 @default.
• W2912071335 creator A5013754928 @default.
• W2912071335 creator A5015357573 @default.
• W2912071335 creator A5021059238 @default.
• W2912071335 creator A5022541563 @default.
• W2912071335 creator A5022650568 @default.
• W2912071335 creator A5023214494 @default.
• W2912071335 creator A5024573751 @default.
• W2912071335 creator A5037169725 @default.
• W2912071335 creator A5056916024 @default.
• W2912071335 creator A5074089943 @default.
• W2912071335 creator A5075519499 @default.
• W2912071335 creator A5079367282 @default.
• W2912071335 creator A5080485119 @default.
• W2912071335 creator A5085010022 @default.
• W2912071335 date "2018-11-29" @default.
• W2912071335 modified "2023-09-27" @default.
• W2912071335 title "Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131" @default.
• W2912071335 doi "https://doi.org/10.1182/blood-2018-99-116180" @default.
• W2912071335 hasPublicationYear "2018" @default.
• W2912071335 type Work @default.
• W2912071335 sameAs 2912071335 @default.
• W2912071335 citedByCount "8" @default.
• W2912071335 countsByYear W29120713352019 @default.
• W2912071335 countsByYear W29120713352020 @default.
• W2912071335 countsByYear W29120713352021 @default.
• W2912071335 countsByYear W29120713352022 @default.
• W2912071335 countsByYear W29120713352023 @default.
• W2912071335 crossrefType "journal-article" @default.
• W2912071335 hasAuthorship W2912071335A5001477884 @default.
• W2912071335 hasAuthorship W2912071335A5006250220 @default.
• W2912071335 hasAuthorship W2912071335A5010578315 @default.
• W2912071335 hasAuthorship W2912071335A5013754928 @default.
• W2912071335 hasAuthorship W2912071335A5015357573 @default.
• W2912071335 hasAuthorship W2912071335A5021059238 @default.
• W2912071335 hasAuthorship W2912071335A5022541563 @default.
• W2912071335 hasAuthorship W2912071335A5022650568 @default.
• W2912071335 hasAuthorship W2912071335A5023214494 @default.
• W2912071335 hasAuthorship W2912071335A5024573751 @default.
• W2912071335 hasAuthorship W2912071335A5037169725 @default.
• W2912071335 hasAuthorship W2912071335A5056916024 @default.
• W2912071335 hasAuthorship W2912071335A5074089943 @default.
• W2912071335 hasAuthorship W2912071335A5075519499 @default.
• W2912071335 hasAuthorship W2912071335A5079367282 @default.
• W2912071335 hasAuthorship W2912071335A5080485119 @default.
• W2912071335 hasAuthorship W2912071335A5085010022 @default.
• W2912071335 hasConcept C126322002 @default.
• W2912071335 hasConcept C143998085 @default.
• W2912071335 hasConcept C2778041864 @default.
• W2912071335 hasConcept C2778461978 @default.
• W2912071335 hasConcept C2779823535 @default.
• W2912071335 hasConcept C2781059491 @default.
• W2912071335 hasConcept C2781107101 @default.
• W2912071335 hasConcept C2909962599 @default.
• W2912071335 hasConcept C71924100 @default.
• W2912071335 hasConcept C90924648 @default.
• W2912071335 hasConceptScore W2912071335C126322002 @default.
• W2912071335 hasConceptScore W2912071335C143998085 @default.
• W2912071335 hasConceptScore W2912071335C2778041864 @default.
• W2912071335 hasConceptScore W2912071335C2778461978 @default.
• W2912071335 hasConceptScore W2912071335C2779823535 @default.
• W2912071335 hasConceptScore W2912071335C2781059491 @default.
• W2912071335 hasConceptScore W2912071335C2781107101 @default.
• W2912071335 hasConceptScore W2912071335C2909962599 @default.
• W2912071335 hasConceptScore W2912071335C71924100 @default.
• W2912071335 hasConceptScore W2912071335C90924648 @default.
• W2912071335 hasIssue "Supplement 1" @default.
• W2912071335 hasLocation W29120713351 @default.
• W2912071335 hasOpenAccess W2912071335 @default.
• W2912071335 hasPrimaryLocation W29120713351 @default.
• W2912071335 hasRelatedWork W134191759 @default.
• W2912071335 hasRelatedWork W1608292346 @default.
• W2912071335 hasRelatedWork W1966099453 @default.
• W2912071335 hasRelatedWork W2001609557 @default.
• W2912071335 hasRelatedWork W2055000007 @default.
• W2912071335 hasRelatedWork W2084181007 @default.
• W2912071335 hasRelatedWork W2119381495 @default.
• W2912071335 hasRelatedWork W373319614 @default.
• W2912071335 hasRelatedWork W4233902207 @default.
• W2912071335 hasRelatedWork W4287930268 @default.
• W2912071335 hasVolume "132" @default.
• W2912071335 isParatext "false" @default.
• W2912071335 isRetracted "false" @default.
• W2912071335 magId "2912071335" @default.
• W2912071335 workType "article" @default.